

Article

In Vitro Cytotoxic Evaluation and Apoptotic Effects of *Datura innoxia* Grown in Saudi Arabia and Phytochemical Analysis

Mohammed Al-Zharani ^{1,*}, Fahd A. Nasr ², Ali S. Alqahtani ^{2,3}, Mary Anne W. Cordero ⁴, Amal A. Alotaibi ^{4,*}, Asmatanzeem Bepari ⁴, Saud Alarifi ⁵, Ali Daoud ⁵, Ibrahim O. Barnawi ⁶ and Haytham M. Daradka ⁶

¹ Biology Department, College of Science, Imam Mohammad ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia

² Medicinal Aromatic, and Poisonous Plants Research Centre, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia; fnasr@ksu.edu.sa (F.A.N.); alalqahtani@ksu.edu.sa (A.S.A.)

³ Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia

⁴ Basic Science Department, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia; macordero@pnu.edu.sa (M.A.W.C.); ambepari@pnu.edu.sa (A.B.)

⁵ Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia; salarifi@ksu.edu.sa (S.A.); aalidaoud@ksu.edu.sa (A.D.)

⁶ Department of Biological Sciences, College of Science, Taibah University, Madina 41321, Saudi Arabia; Abmnawy@taibahu.edu.sa (I.O.B.); Hdaradka@taibahu.edu.sa (H.M.D.)

* Correspondence: mmyalzharani@imamu.edu.sa (M.A.-Z.); amaalotaibi@pnu.edu.sa (A.A.A.)



Citation: Al-Zharani, M.; Nasr, F.A.; Alqahtani, A.S.; Cordero, M.A.W.; Alotaibi, A.A.; Bepari, A.; Alarifi, S.; Daoud, A.; Barnawi, I.O.; Daradka, H.M. In Vitro Cytotoxic Evaluation and Apoptotic Effects of *Datura innoxia* Grown in Saudi Arabia and Phytochemical Analysis. *Appl. Sci.* **2021**, *11*, 2864. <https://doi.org/10.3390/app11062864>

Academic Editors: Adriana Basile and Carmela Spagnuolo

Received: 1 February 2021

Accepted: 10 March 2021

Published: 23 March 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: *Datura innoxia* is an important species of Solanaceae family with several purposes in folk medicine. This study intends to explore the cytotoxic effect of *D. innoxia* on various cancer cell proliferation. *D. innoxia* ethanolic extract's effect on the progression of the cell cycle and the induction of apoptosis were investigated by flow cytometry. Further, real-time PCR was employed to confirm apoptosis initiation. In addition, active phytochemicals of *D. innoxia* was identified by gas chromatography–mass spectroscopy (GC-MS). The cell viability study revealed that the ethanolic extract of *D. innoxia* demonstrated potent cytotoxicity, with an IC₅₀ value of 10 µg/mL against LoVo colon cancer cells. Cell cycle staining with propidium iodide revealed that *D. innoxia* treatment leads to cell accumulation in the sub-G1 phase. Using the Annexin V-FITC/PI assay, the ethanolic extract was found to cause a dose-dependent increase in early and late apoptosis when compared to control cells. Apoptosis as the mode of cell death was also confirmed by the increased expression of p53, bax and caspase-8, -9, and -3 along with downregulation of Bcl-2. GC-MS analysis displayed that 3,5-Dihydroxybenzoic acid (16.53%), heneicosyl formate (14.14%), 2,3-dimethyl-3-pentanol (12.89%), 2-hydroxy-4-methyl pentanoic acid (5.19%) were the main phytoconstituents. These findings conclude that *D. innoxia* causes cell death through apoptosis, suggesting more attention should be paid to further exploration of the active components from *D. innoxia* responsible for the observed activities.

Keywords: *Datura innoxia*; LoVo; antiproliferation; caspases

1. Introduction

Cancer is still a major health issue, and the incidence of cancer related deaths is increasing around the globe [1]. The female breast, lung and colorectal cancers types are among the most commonly diagnosed cancers globally and continue to be the leading cause of cancer related death worldwide [2]. Although mainly unsuccessful and leading to many deaths due to their side effects, the use of conventional treatments to treat cancer is still the most common option of treatment. However, the development of new drugs from natural sources with fewer side effects is becoming promising field in cancer research [3]. Plants are still a promising reservoir for a novel chemical compound in the cancer research area [4]. Many well-known anticancer drugs, such as paclitaxel and camptothecins, are isolated from plant-derived products [5]. With a different biogeographic region, Saudi Arabia provides a remarkably rich source for medicinal plants that have anticancer properties [6,7].

The genus *Datura* belongs to Solanaceae family and comprises about 20 species that grow worldwide [8]. These plants have been used in folk medicine to treat different diseases, including asthma, gastric pain, and indigestion. Other reported medicinal uses of the plant are anti-inflammatory properties, stimulation of the nervous system, and the treatment of dental and skin infections [9]. Various phytoconstituents have been reported in this genus including alkaloids, atropine and scopolamine [10], carotenes and coumarins [11] and saponins [12].

Datura innoxia belongs to the Solanaceae family and it is used in folk medicine to treat several ailments, including skin eruptions, colds, and nervous disorders [13]. Additionally, several medicinal purposes for *D. innoxia* have been reported, such as antispasmodic, pacifying, pain relief, and treating respiratory ailments [14]. The other phytochemicals documented in the plant like phenols, flavonoids, saponins, tannins, glycosides, and resins have analgesic anti-inflammatory, antibacterial as well as antipyretic activities [15–17].

The cytotoxicity of *D. innoxia* against different cancer cells has been reported [18,19]. However, exploring the mode of cell death induced by *D. innoxia* extract still needs more investigation. To our knowledge, there are no reports regarding the activity of *D. innoxia* related to cell cycle arrest and apoptosis induction in LoVo colon cancer cells. Additionally, this study is the initial report documented the phytoconstituents present in *D. innoxia* grown in Saudi Arabia.

2. Materials and Methods

2.1. Plant Collection and Authentication

The fresh aerial parts of *D. innoxia* were collected from Al-Madinah Al-Munawara, Saudi Arabia, in March 2019. The plant material was authenticated by Professor Sami Zalat, Biology Department, College of Science, Taibah University, Saudi Arabia. The plant material was cleaned with water and then rinsed with distilled water. Thereafter, it was dried under shade at room temperature for 10 days. Three hundred grams of powdered plant material were extracted by submerging the plant powder with ethanol and deionized water (70/30 v/v) for 48 h using a Soxhlet apparatus. Next, the mixture was centrifuged at $2500 \times g$, and the collected supernatant was concentrated under reduced pressure in a rotary evaporator. The crude extract was kept at $-20\text{ }^{\circ}\text{C}$ for future use.

2.2. Cell Viability (MTT Assay)

Different human cancer cell lines of various origin was maintained in appropriate medium DMEM (Gibco, USA). The medium was complemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Gibco, USA). Cells were maintained in an incubator containing humidified atmosphere of 95% air and 5% CO_2 at $37\text{ }^{\circ}\text{C}$. MTT reduction assay was carried out to assess the antiproliferation activity as previously described [20]. Briefly, A549 (lung), LoVo (colon), MCF-7 and MDA-MB-231 (breast) cancer cells were plated in 24-multiwell culture plates at 5×10^4 cells per ml and allowed to adhere for 24 h. Cells were incubated with extract at various concentrations (100, 50, 25 and $12.5\text{ }\mu\text{g/mL}$) as well as DMSO as a vehicle control (0.1 v/v final concentration). At the end of incubation (48 h), $100\text{ }\mu\text{L}$ of MTT (Sigma Aldrich, St. Louis, MO, USA) was added to each well. After 4 h, the medium was discarded, and the formazan crystals were dissolved with isopropanol. The absorbance was measured at 570 nm with BioTek plate reader (USA). Extract concentration that decreases the number of viable cells into half (IC_{50}) was computed using the program OriginPro 8.5 Software.

2.3. Cell Cycle Analysis

Cell cycle analysis was conducted by flow cytometry using propidium iodide (PI, BioLegend, San Diego, CA, USA) staining. It was done by plating the LoVo cells in 6-multiwell culture plates at 5×10^4 cells per ml for 24 h. After treatment with *D. innoxia* ethanolic extract (5 and $10\text{ }\mu\text{g/mL}$) as well as a vehicle for 48 h, both floating and attached cells were collected, and washed with cold PBS. The cells were then permeabilized and

fixed in ice cold, 70% (*v/v*) ethanol for 1 h at 4 °C. Finally, cells were incubated with staining solution (50 µg/mL PI and 20 µg/mL RNase A in PBS) at 37 °C for 15 min. Cell cycle phase analysis by flow cytometry was done using a Flow Cytometer (Beckman Coulter Inc. Brea, CA, USA)

2.4. FITC Annexin V/PI Apoptosis Detection

LoVo cells were seeded at 5×10^4 cells/mL in 6 well culture plates, using 2 mL per well, and treated with 5 and 10 µg/mL of ethanolic *D. innoxia* extract and vehicle control. After 48 h of treatment and incubation, the LoVo cells were washed with ice-cold PBS, then the cells were stained following the Annexin V-FITC/PI Kit protocol (BioLegend, CA, USA). In brief, after centrifugation, the supernatant was discarded and cell pellets were resuspended in ice-cold 1X binding buffer (100 µL). Annexin V-FITC (5 µL) and PI (5 µL) were added to each tube. Tubes were then mixed and incubated for 15 min in the dark. Samples were read on a Beckman Coulter FACSscan flow cytometer (Cytomics FC 500; Beckman Coulter, Brea, CA, USA).

2.5. Gene Quantification by qRT-PCR

TRIzol reagent (Invitrogen, Waltham, MA, USA) was used for the total RNA extraction [21] of untreated cells and treated cells, with *D. innoxia* ethanolic extract at 5 and 10 µg/mL and vehicle for 48 h. Total extracted RNA (1 µg) was reverse transcribed using Promega cDNA Synthesis kit (Promega, CA, USA). Real time PCR master mix for apoptosis related genes was prepared according to the previous protocol [22]. The amounts of the mRNA transcripts were measured using the Applied Biosystems 7500 Fast real time PCR detection system (Applied Biosystems, Foster City, CA, USA). The thermo cycling conditions were established as 5 min at 95 °C, followed by 36 cycles of 15 s at 95 °C, 30 s at 60 °C and 30 s at 72 °C. Each reaction was conducted in triplicate and the $2^{-\Delta\Delta C_t}$ method was applied to quantify the mean difference between control and treated samples and GAPDH was used as an internal control. The designed forward (F) and reverse (R) primers sequences are listed in (Table 1).

Table 1. Primer sequences for quantitative real-time polymerase chain reaction (qRT-PCR).

	Gene Name	Forward Primer Sequences	Reverse Primer Sequences
1	P53	5'-TGGCTCTGACTGTACCACCATCC-3'	5'-CAGCTCTCGGAACATCTCGAAGC-3'
2	Bax	5'-GGA TGC GTC CAC CAA GAA G-3'	5'-CCT CTG CAG CTC CAT GTT AC-3'
3	Bcl-2	5'-GTG GAT GAC TGA GTA CCT GAA C-3'	5'-GCC AGG AGA ATT CAA ACA GAG G-3'
4	Caspase 9	5'-CAG GCC CCA TAT GAT CGA GG-3'	5'-TCG ACA ACT TTG CTG CTT GC-3'
5	Caspase 8	5'-CTG GTC TGA AGG CTG GTT GT-3'	5'-CAG GCT CAG GAA CTT GAG GG-3'
6	Caspase 3	5'-CTG GTT TTC GGT GGG TGT G-3'	5'-ACG GCA GGC CTG AAT AAT GAA
7	GAPDH	5'-GGT ATC GTG GAA GGA CTC ATG AC-3'	5'-ATG CCA GTG AGC TTC CCG TTC AGC

2.6. Hoechst 33258 Staining

LoVo cells were grown on 12-well plate for 24 h, and then treated with vehicle as control or with *D. innoxia* ethanolic extract at (5 and 10 µg/mL). After rinsing with PBS, cells were fixed in 4% paraformaldehyde followed by permeabilization in cold methanol. Cells were then washed with PBS, and then incubated with Hoechst 33258 (Sigma, St. Louis, MO, USA) which was prepared in PBS (0.5 µg/mL) and added to LoVo cells for 15 min at the dark. Finally, cells were examined under Zeiss fluorescence microscope a (Zeiss, Wetzlar, Germany).

2.7. GC-MS Analysis of *D. innoxia* Constituents

GC-MS analysis of the *D. innoxia* ethanolic extract was conducted using a Perkin Elmer Clarus 600 GC-MS (PerkinElmer, Waltham, MA, USA). Two microliters of *D. innoxia* extract were placed into the Elite-5MS column (30 m, 0.25 μm thickness, 0.25 μm internal diameter) and components separation was conducted using helium gas as a carrier at a flow of 1 mL/min. The oven temperature was programmed as described previously [20]. The Wiley GC-MS [23] and Adams [24] mass spectral libraries were used to compare comparable mass spectra found for *D. innoxia* constituents.

2.8. Statistical Analysis

All treatments were conducted in triplicates and the standard deviation (SD) of the mean of the three experiments was computed. The Student's two-tailed t-test was performed for each assay to determine significance at $p < 0.05$.

3. Results

3.1. Ethanol Extract of *D. innoxia* Inhibit Cells Proliferation

A549, LoVo, MCF-7 and MDA-MB-231 cancer cells were treated with different *D. innoxia* ethanol extract concentrations to determine its cytotoxic abilities, and thereafter half maximal inhibitory concentration (IC_{50}) values were computed for each cell line. After 48 h of treatment, values were obtained using a dose–response inhibition curve (Table 2). Figure 1 is a dose–response curve for the four cancer cell lines treated with ethanolic extract. The ethanol extract of *D. innoxia* was cytotoxic against all tested cell lines and the LoVo colon cancer cells was the most sensitive cells in terms of IC_{50} values ($\text{IC}_{50} = 10 \mu\text{g/mL}$), therefore, it was selected to conduct the remaining assays.

Table 2. Cytotoxic activity of *D. innoxia* ethanolic extract against different cancer cells.

Sample	Cell Lines and IC_{50} ($\mu\text{g/mL}$)			
	A549	MDA-MB-231	LoVo	MCF-7
<i>D. innoxia</i>	47.76 ± 1.78	32.61 ± 1.29	10.1 ± 0.55	23.97 ± 0.66
Doxorubicin	1.2 ± 0.06	1.3 ± 0.08	1.1 ± 0.8	1.5 ± 0.6




Figure 1. Cytotoxic effect of *D. innoxia* ethanolic extract on various cancer cell lines after 48 h of exposure. Cells were treated as described in the Methods section and cell viability was determined using the MTT assay. Data are expressed as the mean + standard deviation of three experiments.

3.2. *D. innoxia* Causes a Sub-G1 Cells Accumulation

Effect of *D. innoxia* ethanolic extract on cell cycle of LoVo cells was analyzed using propidium iodide via flow cytometry. After treatment with 5 and 10 $\mu\text{g}/\text{mL}$ for 48 h, the sub-G1 phase cells were accumulated to $12.5 \pm 0.5\%$ and 32.9 ± 1 , respectively, (Figure 2), while in the control group it was only $1.6 \pm 0.1\%$. We also observed that the G2/M phase was affected at 10 $\mu\text{g}/\text{mL}$, indicating a cell cycle block or delay at this stage.




Figure 2. Histograms representing DNA contents analysis after 48 h of LoVo cells treatment. LoVo cells were treated with 5 and 10 $\mu\text{g}/\text{mL}$ *D. innoxia* and vehicle control. Cell cycle analysis was recorded on a Beckman Coulter Cytomics FC500 after PI staining.

3.3. Apoptotic Cell Death Quantification of *D. innoxia* Treated Cells

Staining with Annexin V-FITC and propidium iodide was also used to confirm apoptosis induction on LoVo cells by ethanolic *D. innoxia* extract. The results obtained from this experiment are depicted in (Figure 3). A significant increase from $1.7 \pm 0.14\%$ to $15.35 \pm 0.5\%$ and $27.9 \pm 0.5\%$ ($p < 0.05$) of early and late apoptotic cells respectively was recorded after

treatment with 5 $\mu\text{g}/\text{mL}$. In the same manner, an increase to $24.5 \pm 0.7\%$ and $72.6 \pm 0.84\%$ ($p < 0.01$) was recorded for both stages after treatment with 10 $\mu\text{g}/\text{mL}$ (Figure 3).




Figure 3. Dot plots of Annexin V-FITC stained LoVo cells after 48 h exposure to 5 and 10 $\mu\text{g}/\text{mL}$ of *D. innoxia*. (A3: Annexin V-negative; PI-negative), early apoptotic cells (A4: Annexin V-positive; PI-negative), late apoptotic cells (A2: Annexin V-positive; PI-positive) and necrotic cells (A1: Annexin V-negative; PI-positive). A minimum of 20,000 events were read ($n = 3$). (One representative for 3 individual experiments, each performed in triplicate). Data are presented as means \pm SD and the difference was statistically significant at (* $p < 0.05$, ** $p < 0.01$).

3.4. The Quantitative Real-Time PCR Analysis of Apoptosis-Related Genes

Our results indicate that the *D. innoxia* treated cells showed a dose-dependent increase in the levels of apoptosis related genes. The results showed that the p53 and caspase-3, -9, and -8 showed higher upregulation and were significantly upregulated ($p < 0.05$). However, no significant expression was reported for Bax gene in cells treated with *D. innoxia* ethanolic extract. Furthermore, the expression of antiapoptotic Bcl-2 gene was inhibited after treatment in dose-dependent manner (Figure 4).

3.5. *D. innoxia* Causes a DNA Fragmentation

To explore the morphological alterations caused by *D. innoxia* ethanolic extract treatment, LoVo cells were monitored using Hoechst 33258 staining. As compared with the control cells, the features of apoptotic cell death, including nuclear fragmentation in the *D. innoxia* treated cells, were noticed (Figure 5). These results elucidated that the inhibition of *D. innoxia* ethanolic extract on LoVo cells growth was linked with its induction of apoptosis.




Figure 4. Gene expression levels in LoVo cells, treated with 5 and 10 µg/mL of *D. innoxia* for 48 h. Apoptosis related gene expression levels of p53, bax, bcl-2 and caspases 9, 8, 3 were determined by quantitative real-time PCR. GAPDH was used as an internal control. The significant differences from control are indicated by * $p < 0.05$.




Figure 5. Efficacy of *D. innoxia* in inducing apoptosis in LoVo cells. The cells were stained with Hoechst dye for nuclear morphology after treatments with *D. innoxia* ethanolic extract and fluorescent images were obtained. Characteristics of apoptosis, such as nuclear derangement, are observed in LoVo treated cells (arrows) compared to control cells.

3.6. Identification of *D. innoxia* Components by GC-MS



The analysis of the *D. innoxia* by GC-MS identified 50 compounds from the ethanolic extract. The retention time and the percentage amounts of the compositions are displayed in (Table 3). The identified compounds are represented in the order of their elution on the HP Innowax column (Figure 6). 3,5-dihydroxybenzoic acid (16.53%), Heneicosyl formate (14.14%) and 2,3-dimethyl-3-pentanol (12.89%) and 2-hydroxy-4-methyl pentanoic acid (5.19%) were the primary constituents (Figure 7). The remaining compounds are present in small proportions (Table 3).

Table 3. The identified compounds from *D. innoxia* ethanolic extract by GC-MS.

Compound Name	Chemical Formula	Molecular Weight (g/mol)	RT (min)	Area%
Bicyclo [3.2.0]heptane	C ₇ H ₁₂	96.17	5.41	0.26
1-Propene-1-thiol	C ₃ H ₆ S	74.15	5.525	0.73
3-Methyl-isoxazol-5(4H)-one	C ₄ H ₅ NO ₂	99.09	6.027	0.32
(Z)-3-Methyl-2-hexene	C ₇ H ₁₄	98.19	6.67	0.31
Alpha.Aminoxy-propionic acid	C ₃ H ₇ NO ₃	105.09	6.861	0.35
2,3-Dimethyl-3-pentanol	C ₇ H ₁₆ O	116.2	7.338	12.89
3,4,6-Tri-O-methyl-d-glucose	C ₉ H ₁₈ O ₆	222.24	8.693	0.51
3,3-Dimethyl-2-pentanol	C ₇ H ₁₆ O	116.2	8.814	2.09
2,6-diethyl-Benzenamine	C ₁₀ H ₁₅ N	149.23	9.393	0.32
3-(1-Cyclopentyl) furan	C ₉ H ₁₀ O	134.17	9.475	0.44
<i>N,N</i> -dimethyl-Propanamide	C ₅ H ₁₁ NO	101.15	9.933	1.03
4-methyl-1,3-Dioxane	C ₅ H ₁₀ O ₂	102.13	10.493	2.2
3-methyl-Benzoyl chloride	C ₈ H ₇ ClO	154.59	11.212	0.65
2-hydroxy-4-methyl Pentanoic acid	C ₆ H ₁₂ O ₃	132.16	12.109	5.19
Phenoxyacetamide	C ₈ H ₉ NO ₂	151.16	12.714	3.65
1-Heptynylbenzene	C ₁₃ H ₁₆	172.27	13.42	0.5
Palmitoleic acid	C ₁₆ H ₃₀ O ₂	254.41	15.971	0.3
3-(2-furanyl)-2-Propenal	C ₇ H ₆ O ₂	122.12	16.098	0.36
Megastigmatrienone	C ₁₃ H ₁₈ O	190.28	16.321	0.46
2-nitrophenyl azide	C ₆ H ₄ N ₄ O ₂	164.12	16.881	0.5
Spiro [2.3] hexan-4-one, 5,5-diethyl	C ₁₀ H ₁₆ O	152.23	17.224	0.33
3-Nonyn-1-ol	C ₉ H ₁₆ O	140.22	17.6	0.29
Methyl 3-methoxy-4-nitrobenzoate	C ₉ H ₉ NO ₅	211.17	18.166	0.61
Cyclopropaneoctanal	C ₁₁ H ₂₀ O	168.28	18.242	0.6
(6R)-6alpha-[(Z)-1,3-Butadienyl]-1,4-cycloheptadiene	C ₁₁ H ₁₄	146.23	18.541	0.39
2,3,3,4,5-pentaethyl 1,2,5-Oxadiborolane	C ₁₂ H ₂₆ O ₂ O	207.96	19.082	1.26
Cyclotridecane	C ₁₃ H ₂₆	182.35	19.158	0.6
Dolichodial	C ₁₀ H ₁₄ O ₂	166.21	19.527	0.44
<i>p</i> -Menth-8(10)-en-9-ol	C ₁₀ H ₁₈ O	154.25	19.96	0.61
1,4-Icosanediol	C ₂₀ H ₄₂ O ₂	314.5	20.628	0.95
13-Tetradec-11-yn-1-ol	C ₁₄ H ₂₄ O	208.34	20.736	0.26
9,17-Octadecadienal	C ₁₈ H ₃₂ O	264.4	21.137	0.29
1,19-Eicosadiene	C ₂₀ H ₃₈	278.5	21.678	1.35
Heneicosyl formate	C ₂₂ H ₄₄ O ₂	340.6	21.792	14.14
8-Tetradecen-1-ol	C ₁₄ H ₂₈ O	212.37	22.053	4.21
3-Methoxybenzylamine	C ₈ H ₁₁ NO	137.18	22.282	0.7
Linoleic acid	C ₁₈ H ₃₂ O ₂	280.4	22.352	0.86
Bicyclo [6.1.0] non-1-ene	C ₉ H ₁₄	122.21	22.473	0.33
4-Isopropenylcyclohexanone	C ₉ H ₁₄ O	138.21	22.708	2.89
Cyclohexane, 1,1'-methylenebis	C ₁₃ H ₂₄	180.33	23.045	2.55

Table 3. Cont.

Compound Name	Chemical Formula	Molecular Weight (g/mol)	RT (min)	Area%
Z, Z-3,13-Octadecadien-1-ol acetate	C ₂₀ H ₃₆ O ₂	308.5	23.548	0.6
9-Methyl-Z, Z-10,12-hexadecadien-1-ol acetate	C ₁₉ H ₃₄ O ₂	294.5	23.618	0.54
2,10-dimethyl-9-Undecenal	C ₁₃ H ₂₄ O	196.33	23.917	0.35
3,5-Dihydroxybenzoic acid	C ₇ H ₆ O ₄	154.12	24.184	16.53
7-Pentadecyne	C ₁₅ H ₂₈	208.38	24.954	0.25
1,3,12-Nonadecatriene	C ₁₉ H ₃₄	262.5	25.139	0.49
1,5,9-Cyclododecatriene	C ₁₂ H ₁₈	162.27	26.532	0.79
Monoelaidin	C ₂₁ H ₄₀ O ₄	356.5	27.41	1.23
2-methyl-5-(1-methyl ethenyl)-Cyclohexanol	C ₁₀ H ₁₈ O	154.25	27.76	1.21
Z-(13,14-Epoxy) tetradec-11-en-1-ol acetate	C ₁₆ H ₂₈ O ₃	268.39	27.868	1.24

Figure 6. GC-MS chromatogram of *D. innoxia* ethanolic extract.Figure 7. Major constituent in *D. innoxia*.

4. Discussion

Datura innoxia is a valuable medicinal plant rich in different phytochemicals with a broad medicinal property [25]. In this study, *D. innoxia* was extracted by hydroalcoholic solvent in order to obtain the maximum amount and diversity of biologically active phytochemicals. The results of the present study presented that the *D. innoxia* ethanolic extract exerted a cytotoxic effect on various cancer cells, with high potent activity against LoVo human colon cancer cells. We have also demonstrated that *D. innoxia* ethanolic extract induces a cell cycle arrest at the sub-G1 phase and more precisely an apoptotic cell death. This finding is supported by several pieces of evidence including Annexin V-FITC/PI labeling as well as the activation of the apoptosis signaling molecules. This finding is in line with a prior study that reported a strong antiproliferative effect of *D. innoxia* leaf methanolic extracts against colon (HCT-15) and liver HepG-2 cancer cells [26]. A potent cytotoxic effect against the THP-1 (human leukemia) cell line with a close IC₅₀ value (4.52 µg/mL) was also documented for the *D. innoxia* grown in Pakistan [27]. In the same manner, the cytotoxic effect against the MCF-7 cell line was also reported [18] for *D. innoxia* grown in Iran. This variation in IC₅₀ values may result from different *D. innoxia* geographical sources, growing conditions and various cell types used [28]. National Cancer Institute (NCI, USA) criteria considered a plant crude extract with IC₅₀ value less than 20 µg/mL a suitable extract for in vitro cytotoxic activity [29]. Based on this, *D. innoxia* displayed potent cytotoxic activity against LoVo with IC₅₀ 10 µg/mL; therefore, LoVo cells were selected to assert the inhibition mechanisms exerted by this extract.

The cell cycle distribution of LoVo cells treated with *D. innoxia* was analyzed to explore the growth inhibition mechanism. It was observed that cells treatments with *D. innoxia* accumulated at the sub-G1 cells phase, and this result proposed that LoVo cells undergo apoptosis since the accumulation of the cells in this stage is considered as a biomarker for DNA damage as well as an apoptotic cell death marker [30]. Confirmation of apoptosis induction was then verified through Annexin V-FITC/PI apoptosis detection assay, which is extensively used to discriminate living cells from both early and late apoptosis [31]. It was noted that *D. innoxia* resulted in a strong shift to early and late apoptotic cell populations and no necrotic cells were detected, which emphasizes that *D. innoxia* extract exerted apoptosis cell death mode. The indications of the dual staining of Annexin-V/PI and the accumulation of cells in the sub-G1 phase, as well as nuclear derangement which was observed with Hoechst staining after treatment with *D. innoxia* ethanolic extract, clearly indicates that the cells are going in apoptosis. In fact, the induction of the apoptotic signaling pathways to trigger cancer cell death is the main mechanism for most anticancer drugs [32].

Apoptosis is a highly gene regulated process and various gene families, such as the P53 and the Bcl-2 family, are implicated in apoptotic cell death [33]. To support the flow cytometry results, the expression of the genes involved in the apoptosis pathway was analyzed using the qRT-PCR technique. Our results clearly proved that the extract treatments led to a decrease in the antiapoptotic Bcl-2 gene and an increase in the proapoptotic Bax gene, as well as activating caspase genes in the treated groups compared to the control, suggesting that *D. innoxia* acts through a caspase-dependent apoptosis pathway. A similar event was observed in a recent study which reported that *D. innoxia* extract induced apoptosis through increasing the expression of P53, BAX/BCL2 ratio, caspase 9, 3, 6, 7 on human chronic myeloid leukemia cells (K562 cells) [34]. Altogether this study and our study support the apoptosis-inducing effect of *D. innoxia* against different cancer cells.

Many species of the Solanaceae family are rich in calystegin, which has an inhibitory property against cancer [35]. The Lectin was also isolated from *D. innoxia* seeds and it has also shown antiproliferative activity against human cancer cell lines [36]. GC/MS is also a useful and reliable method for the rapid identification of complex plant extracts [37]. The 3,5-dihydroxybenzoic acid, which was detected as a major constituent of *D. innoxia* in this study, has shown an inhibitory effect against colorectal cancer cells' growth [38], suggesting a possible role for this compound in the observed activity against LoVo colon cells.

The plant extracts' medicinal effects could be primarily attributed to their secondary products, which act synergistically rather than as a single compound [39]. As aforementioned, *D. innoxia* contains a combination of several compounds that have anticancer effects, so it can be concluded that the anticancer effects observed in the extract are associated with the presence of these compounds.

5. Conclusions

The *D. innoxia* ethanolic extract exerted antiproliferation capacity against various cancer cells. In particular, we have illustrated that *D. innoxia* ethanolic extract affects the growth of the LoVo colon cancer cell line successfully by inducing cell death. Our data have shown the potential role of *D. innoxia* in activating apoptosis via increasing the SubG1 phase as well as causing dose-dependent increases in early and late apoptosis cells population. Besides, apoptosis initiation induced by *D. innoxia* was confirmed by the upregulation of apoptosis gene markers in LoVo cells. This study provides preliminary data that proposes *D. innoxia* as a valuable source of potentially new natural anticancer compound(s) that act by triggering apoptotic cell death. Further research is required to find effective compounds as well as the cellular and molecular mechanisms involved.

Author Contributions: Conceptualization, M.A.-Z. and A.S.A.; methodology, F.A.N., M.A.-Z., I.O.B. and H.M.D.; validation, A.S.A. and F.A.N.; investigation, writing—original draft preparation; M.A.-Z., F.A.N.; writing—review and editing, M.A.W.C. and A.A.A.; project administration, S.A. and A.D.; funding acquisition A.B. and A.A.A. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University, through the Research Groups Program Grant no. (RGP-1442-0033).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The raw data used and/or analyzed during the current study will be available from the corresponding author on reasonable request.

Acknowledgments: This work was funded by the Deanship of Scientific Research at Princess Nourah bint Abdulrahman University, through the Research Groups Program Grant no. (RGP-1442-0033).

Conflicts of Interest: The authors declare that they have no competing interests.

References

1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2018**, *68*, 394–424. [[CrossRef](#)] [[PubMed](#)]
2. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2021**. [[CrossRef](#)]
3. Zhang, Q.-Y.; Wang, F.-X.; Jia, K.-K.; Kong, L.-D. Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects. *Front. Pharm.* **2018**, *9*, 1253. [[CrossRef](#)]
4. Iqbal, J.; Abbasi, B.A.; Mahmood, T.; Kanwal, S.; Ali, B.; Shah, S.A.; Khalil, A.T. Plant-derived anticancer agents: A green anticancer approach. *Asian Pac. J. Trop. Biomed.* **2017**, *7*, 1129–1150. [[CrossRef](#)]
5. Desai, A.G.; Qazi, G.N.; Ganju, R.K.; El-Tamer, M.; Singh, J.; Saxena, A.K.; Bedi, Y.S.; Taneja, S.C.; Bhat, H.K. Medicinal plants and cancer chemoprevention. *Curr. Drug Metab.* **2008**, *9*, 581–591. [[CrossRef](#)]
6. Al-Eisawi, D.M.; Al-Ruzayza, S. The flora of holy Mecca district, Saudi Arabia. *Int. J. Biodivers. Conserv.* **2015**, *7*, 173–189.
7. Al-Zahrani, A.A. Saudi anti-human cancer plants database (SACPD): A collection of plants with anti-human cancer activities. *Oncol. Rev.* **2018**, *12*, 349. [[CrossRef](#)]
8. Evans, W.; Ghani, A.; Woolley, V.A. Distribution of littorine and other alkaloids in the roots of *Datura* species. *Phytochemistry* **1972**, *11*, 2527–2529. [[CrossRef](#)]
9. Pandey, M.; Saraswati, S.; Agrawal, S. Antiproliferative effects of *Datura innoxia* extract in cervical HeLa cell line. *J. Pharm. Res.* **2011**, *4*, 1124–1126.
10. Giral, F.; Hidalgo, C. Presence of alkaloids in Mexican plants. *Int. J. Crude Drug Res.* **1983**, *21*, 1–13. [[CrossRef](#)]
11. El-Tawil, B. Chemical constituents of indigenous plants used in native medicine of Saudi Arabia. II. *Arab Gulf J. Sci. Res.* **1983**.

12. Aynehchi, Y.; Salehi Sormaghi, M.; Amin, G.; Khoshkhow, M.; Shabani, A. Survey of Iranian plants for saponins, alkaloids, flavonoids and tannins. III. *Int. J. Crude Drug Res.* **1985**, *23*, 33–41. [[CrossRef](#)]
13. Shama, A.I.; Abd-Kreem, Y.; Fadowa, A.; Samar, R.; Sabahelkhier, M. In vitro antibacterial and antifungal activity and *Datura innoxia* extracts. *Int. J. Environ.* **2014**, *3*, 173–185. [[CrossRef](#)]
14. Gajendran, B.; Durai, P.; Varier, K.M.; Liu, W.; Li, Y.; Rajendran, S.; Nagarathnam, R.; Chinnasamy, A. Green synthesis of silver nanoparticle from *Datura innoxia* flower extract and its cytotoxic activity. *BioNanoScience* **2019**, *9*, 564–572. [[CrossRef](#)]
15. Cook, N.C.; Samman, S. Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources. *J. Nutr. Biochem.* **1996**, *7*, 66–76. [[CrossRef](#)]
16. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Rémésy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am. J. Clin. Nutr.* **2005**, *81*, 230S–242S. [[CrossRef](#)] [[PubMed](#)]
17. Hostettmann, K.; Marston, A. *Saponins*; Cambridge University Press: Cambridge, UK, 2005.
18. Cheshomi, H.; Aldaghi, L.S.; Rezaei Seresht, H. Cytotoxicity of the methanol extract of *datura innoxia* petals on MCF-7 and HEK-293 cell lines. *J. Biomed.* **2016**, *1*, e6623. [[CrossRef](#)]
19. Chamani, E.; Ebrahimi, R.; Khorsandi, K.; Meshkini, A.; Zarban, A.; Sharifzadeh, G. In vitro cytotoxicity of polyphenols from *Datura innoxia* aqueous leaf-extract on human leukemia K562 cells: DNA and nuclear proteins as targets. *Drug Chem. Toxicol.* **2020**, *43*, 138–148. [[CrossRef](#)]
20. Nasr, F.A.; Noman, O.M.; Alqahtani, A.S.; Qamar, W.; Ahamad, S.R.; Al-Mishari, A.A.; Alyhya, N.; Farooq, M. Phytochemical constituents and anticancer activities of *Tarhnanthus camphoratus* essential oils grown in Saudi Arabia. *Saudi Pharm. J.* **2020**, *28*, 1474–1480. [[CrossRef](#)] [[PubMed](#)]
21. Rio, D.C.; Ares, M., Jr.; Hannon, G.J.; Nilsen, T.W. Purification of RNA using TRIzol (TRI reagent). *Cold Spring Harb. Protoc.* **2010**, *2010*. [[CrossRef](#)]
22. Abutaha, N.; Nasr, F.A.; Al-zharani, M.; Alqahtani, A.S.; Noman, O.M.; Mubarak, M.; Abdelhabib, S.; Wadaan, M.A. Effects of hexane root extract of *ferula hermonis* boiss. On human breast and colon cancer cells: An in vitro and in vivo study. *Biomed. Res. Int.* **2019**, *2019*, 3079895. [[CrossRef](#)] [[PubMed](#)]
23. McLafferty, F.W.; Stauffer, D.B. *The Wiley/NBS Registry of Mass Spectral Data*; Wiley: New York, NY, USA, 1989; Volume 1.
24. Adams, R.P. *Identification of Essential oil Components by Gas Chromatography/Mass Spectrometry*; Allured Publishing Corporation: Carol Stream, IL, USA, 2007; Volume 456.
25. Jaafar, F.R.; Ajeena, S.J.; Mehdy, S.S. Anti-inflammatory impacts and analgesiac activity of aqueous extract *Datura innoxia* leaves against induced pain and inflammation in mice. *J. Entomol. Zool. Stud.* **2018**, *6*, 1894–1899.
26. Arulvasu, C.; Babu, G.; Manikandan, R.; Srinivasan, P.; Sellamuthu, S.; Prabhu, D.; Dinesh, D. Anti-cancer effect of *Datura innoxia* P. Mill. Leaf extract in vitro through induction of apoptosis in human Colon Adenocarcinoma and larynx cancer cell lines. *J. Pharm. Res.* **2010**, *3*, 1485–1488.
27. Fatima, H.; Khan, K.; Zia, M.; Ur-Rehman, T.; Mirza, B.; Haq, I.-u. Extraction optimization of medicinally important metabolites from *Datura innoxia* Mill.: An in vitro biological and phytochemical investigation. *BMC Complement. Altern. Med.* **2015**, *15*, 376. [[CrossRef](#)]
28. Uğur, D.; Güneş, H.; Güneş, F.; Mammadov, R. Cytotoxic Activities of Certain Medicinal Plants on Different Cancer Cell Lines. *Turk. J. Pharm. Sci.* **2017**, *14*, 222–230. [[CrossRef](#)]
29. Boik, J. *Natural Compounds in Cancer Therapy*; Oregon Medical Press: Princeton, MN, USA, 2001.
30. Riccardi, C.; Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. *Nat. Protoc.* **2006**, *1*, 1458–1461. [[CrossRef](#)] [[PubMed](#)]
31. Demchenko, A.P. Beyond annexin V: Fluorescence response of cellular membranes to apoptosis. *Cytotechnology* **2013**, *65*, 157–172. [[CrossRef](#)] [[PubMed](#)]
32. Pistritto, G.; Trisciuglio, D.; Ceci, C.; Garufi, A.; D’Orazi, G. Apoptosis as anticancer mechanism: Function and dysfunction of its modulators and targeted therapeutic strategies. *Aging* **2016**, *8*, 603–619. [[CrossRef](#)] [[PubMed](#)]
33. Kiraz, Y.; Adan, A.; Kartal Yandim, M.; Baran, Y. Major apoptotic mechanisms and genes involved in apoptosis. *Tumour Biol.* **2016**, *37*, 8471–8486. [[CrossRef](#)]
34. Chamani, E.; Rezaei, Z.; Dastjerdi, K.; Javanshir, S.; Khorsandi, K.; Mohammadi, G.A. Evaluation of some genes and proteins involved in apoptosis on human chronic myeloid leukemia cells (K562 cells) by *datura innoxia* leaves aqueous extract. *J. Biomol. Struct. Dyn.* **2020**, *38*, 4838–4849. [[CrossRef](#)] [[PubMed](#)]
35. Diker, D.; Markovitz, D.; Rothman, M.; Sendovski, U. Coma as a presenting sign of *Datura stramonium* seed tea poisoning. *Eur. J. Intern. Med.* **2007**, *18*, 336–338. [[CrossRef](#)] [[PubMed](#)]
36. Singh, R.; Nawale, L.; Sarkar, D.; Suresh, C. Two chitotriose-specific lectins show anti-angiogenesis, induces caspase-9-mediated apoptosis and early arrest of pancreatic tumor cell cycle. *PLoS ONE* **2016**, *11*, e0146110. [[CrossRef](#)] [[PubMed](#)]
37. Iordache, A.; Culea, M.; Gherman, C.; Cozar, O. Characterization of some plant extracts by GC–MS. *Nucl. Instrum. Methods Phys. Res. Sect. B Beam Interact. Mater. At.* **2009**, *267*, 338–342. [[CrossRef](#)]
38. Sankaranarayanan, R.; Valiveti, C.K.; Dachineni, R.; Kumar, D.R.; Lick, T.; Bhat, G.J. Aspirin metabolites 2,3-DHBA and 2,5-DHBA inhibit cancer cell growth: Implications in colorectal cancer prevention. *Mol. Med. Rep.* **2020**, *21*, 20–34. [[CrossRef](#)]
39. Jigna, P.; Rathish, N.; Sumitra, C. Preliminary screening of some folklore medicinal plants from western India for potential antimicrobial activity. *Indian J. Pharmacol.* **2005**, *37*, 408–409.